Sivik Global Healthcare LLC boosted its position in Encompass Health Corporation (NYSE:EHC – Free Report) by 166.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,000 shares of the company’s stock after buying an additional 25,000 shares during the period. Encompass Health makes up about 3.0% of Sivik Global Healthcare LLC’s holdings, making the stock its 16th biggest position. Sivik Global Healthcare LLC’s holdings in Encompass Health were worth $4,860,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of EHC. Transamerica Financial Advisors LLC acquired a new stake in shares of Encompass Health in the 2nd quarter worth $29,000. Toth Financial Advisory Corp acquired a new position in shares of Encompass Health during the third quarter worth about $38,000. Persistent Asset Partners Ltd acquired a new position in shares of Encompass Health during the second quarter worth about $36,000. Keating Financial Advisory Services Inc. purchased a new position in Encompass Health during the second quarter worth about $39,000. Finally, Assetmark Inc. raised its holdings in Encompass Health by 89.6% during the first quarter. Assetmark Inc. now owns 455 shares of the company’s stock worth $44,000 after purchasing an additional 215 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.
Encompass Health Price Performance
Shares of EHC traded up $0.34 during mid-day trading on Tuesday, reaching $124.76. 139,999 shares of the company’s stock were exchanged, compared to its average volume of 1,035,778. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.76. The company has a 50-day simple moving average of $121.81 and a two-hundred day simple moving average of $110.85. Encompass Health Corporation has a 52-week low of $92.77 and a 52-week high of $127.99. The company has a market cap of $12.31 billion, a price-to-earnings ratio of 20.32, a PEG ratio of 2.50 and a beta of 0.74.
Encompass Health Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Thursday, October 1st. This is a positive change from Encompass Health’s previous quarterly dividend of $0.19. Encompass Health’s payout ratio is currently 13.68%.
Insiders Place Their Bets
In related news, CEO Mark Tarr sold 173,148 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $125.47, for a total transaction of $21,724,879.56. Following the completion of the sale, the chief executive officer owned 267,814 shares of the company’s stock, valued at approximately $33,602,622.58. This represents a 39.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP John Darby sold 4,858 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $121.09, for a total transaction of $588,255.22. Following the completion of the sale, the executive vice president directly owned 75,041 shares of the company’s stock, valued at $9,086,714.69. The trade was a 6.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 186,912 shares of company stock valued at $23,434,845. Insiders own 1.80% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on EHC shares. Raymond James Financial set a $150.00 price objective on Encompass Health in a report on Monday, September 28th. Wall Street Zen raised Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, September 26th. Barclays raised their price target on Encompass Health from $140.00 to $144.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. UBS Group lifted their price target on Encompass Health from $150.00 to $155.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Truist Financial upped their price objective on Encompass Health from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $148.50.
Get Our Latest Stock Analysis on EHC
Encompass Health Company Profile
Encompass Health Corporation (NYSE:EHC) is a healthcare services company focused on inpatient rehabilitation. Through its network of rehabilitation hospitals, the company provides intensive medical and therapeutic care to patients recovering from conditions such as strokes, brain and spinal cord injuries, hip fractures, amputations, neurological disorders, and other disabling illnesses or injuries.
Its rehabilitation hospitals offer coordinated care from physicians, nurses, therapists, and other healthcare professionals.
Further Reading
- Five stocks we like better than Encompass Health
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
- IonQ Fell 9% on a $1.3 Billion Deal—Is Wall Street Missing Something?
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.
